This compound is a key intermediate in the synthesis of Dabigatran etexilate, a direct thrombin inhibitor used as an anticoagulant for preventing stroke and systemic embolism in patients with atrial fibrillation and for treating deep vein thrombosis. The benzimidazole core with the 4-carbamimidoylphenyl aminomethyl substituent enables specific binding to the thrombin active site, inhibiting fibrin formation. The ethyl ester group enhances solubility during synthesis and serves as a prodrug moiety. It is employed in pharmaceutical research and manufacturing for cardiovascular therapies, with favorable pharmacokinetic properties supporting oral administration.